Transcode Therapeutics Holds ESMO Pitch on RNA‑Based AntagomiR; Stock Remains Flat at $1.68
Transcode Therapeutics (RNAZ) hits a 52‑week low as it prepares to unveil early‑stage TTX‑MC138 data at the ESMO Congress, sparking fresh investor interest.
- TRANSCODE THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read